Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Pieter Sonneveld, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broyl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Gerard M.J. Bos, Ka Lung Wu, Jolanda Droogendijk, Monique C. Minnema, Mario Boccadoro

Blood (2021) 138 (Supplement 1): 1664.

https://doi.org/10.1182/blood-2021-149423

Published: 2021

Journal Articles

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Blood (2021) 138 (Supplement 1): 728.

https://doi.org/10.1182/blood-2021-150913

Published: 2021

Journal Articles

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Monique Minnema, Kazem Nasserinejad, MA, Bouke Hazenberg, MD PhD, Ute Hegenbart, Lucien Noens, MD PhD, Paula F. Ypma, MD, Sonja Zweegman, MD PhD, Lidwine Winnifred Tick, MD PhD, Annemiek Broijl, MD PhD, Harry R. Koene, MD PhD, Gerard M.J. Bos, MD PhD, Pieter Sonneveld, MD PhD, Stefan O. Schoenland, MD

Blood (2016) 128 (22): 4628.

https://doi.org/10.1182/blood.V128.22.4628.4628

Published: 2016

Journal Articles

A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients

Blood (2015) 126 (23): 1357.

https://doi.org/10.1182/blood.V126.23.1357.1357

Published: 2015

Journal Articles

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Blood (2015) 126 (23): 27.

https://doi.org/10.1182/blood.V126.23.27.27

Published: 2015

Journal Articles

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Annemiek Broijl, MDPhD, Marie José Kersten, MD PhD, Wendim Ghidey Alemayehu, PhD, Mark-David Levin, MDPhD, Okke de Weerdt, MD, Edo Vellenga, MDPhD, Ellen Meijer, MDPhD, Shulamiet Wittebol, MDPhD, Rosita Ghiraw-Visser, Marian Stevens-Kroef, PhD, Berna Beverloo, PhD, Gerard M.J. Bos, MDPhD, Pierre W. Wijermans, MDPhD, Henk Lokhorst, MDPhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 4735.

https://doi.org/10.1182/blood.V124.21.4735.4735

Published: 2014

Journal Articles

The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis

Raynier Devillier, MD, Jurjen Versluis, MD, Bronno Van der Holt, PhD, Marie Jose Kersten, MD PhD, Reinier Raymakers, MD PhD, Sonja Zweegman, MD PhD, Gerard M.J. Bos, MDPhD, Nicolaas PM Schaap, Annemiek Broyl, Pieter Sonneveld, MD, Henk Lokhorst, Jan J. Cornelissen, MD PhD

Blood (2014) 124 (21): 1209.

https://doi.org/10.1182/blood.V124.21.1209.1209

Published: 2014

Journal Articles

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

Blood (2014) 124 (21): 179.

https://doi.org/10.1182/blood.V124.21.179.179

Published: 2014

Journal Articles

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Henk Lokhorst, Bronno van der Holt, PhD, Jan Cornelissen, MD, PhD, Marie José Kersten, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Reinier Raymakers, MD, PhD, Monique C. Minnema, MD PhD, Sonja Zweegman, MD PhD, Jeroen JWM Janssen, MD, Mark Zijlmans, MD, Gerard M.J. Bos, Prof MD PhD, Nicolaas PM Schaap, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 2132.

https://doi.org/10.1182/blood.V122.21.2132.2132

Published: 2013

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Blood (2013) 122 (21): 404.

https://doi.org/10.1182/blood.V122.21.404.404

Published: 2013

Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD

Blood (2013) 122 (21): 287.

https://doi.org/10.1182/blood.V122.21.287.287

Published: 2013

Journal Articles

Effective Alloreactive NK Cell Therapy for Breast Cancer In Mice Requires Conditioning with Cyclophosphamide and Total Body Irradiation but Not Bone Marrow Engraftment

Michel Van Gelder, Peter Frings, Catarina Matos, Harry C. Schouten, Gerard M.J. Bos

Blood (2010) 116 (21): 2085.

https://doi.org/10.1182/blood.V116.21.2085.2085

Published: 2010

Journal Articles

Role of Human NK Cells in Dentric-Cell Based Vaccine.

Gerard M.J. Bos, MD, PhD, Janine CHMJ Van Elssen, Joris Vanderlocht, Brigitte LMG Senden-Gijsbers, Wilfred LMG Germeraad

Blood (2008) 112 (11): 1550.

https://doi.org/10.1182/blood.V112.11.1550.1550

Published: 2008

Journal Articles

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Henk Lokhorst, Bronno van der Holt, Sonja Zweegman, MD, PhD, Peter A. Von Dem Borne, MD, PhD, Gerard M.J. Bos, MD, PhD, Sandra Croockewit, MD, PhD, Jan J. Cornelissen, MD, PhD, Marinus van Oers, Martyn Ronald Schaafsma, Harm Sinnige, MD, PhD, Michel Delforge, MD, PhD, Okke de Weerdt, Pierre W Wijermans, Shulamiet Wittebol, MD, PhD, Edo Vellenga, MD, PhD, Asiong Jie, Henriette Berenschot, MD, PhD, Marinus Marwijk-kooy, MD, PhD, Pieter Sonneveld, MD, PhD

Blood (2008) 112 (11): 157.

https://doi.org/10.1182/blood.V112.11.157.157

Published: 2008

Journal Articles

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Blood (2005) 106 (11): 424.

https://doi.org/10.1182/blood.V106.11.424.424

Published: 2005

Journal Articles

Keratinocyte Growth Factor Ameliorates Acute Graft-versus-Host Disease in a Novel Nonmyeloablative Haploidentical Transplantation Model.

Gerard M.J. Bos, MD, PhD, Ariane Vanclee, Ellis Oving, Ludy Lutgens, MD, Nicolaas Deutz, PhD, Harry Schouten, MD, PhD

Blood (2004) 104 (11): 3060.

https://doi.org/10.1182/blood.V104.11.3060.3060

Published: 2004

Journal Articles

Homocysteine Lowering by B Vitamins and the Secondary Prevention of Deep-Vein Thrombosis and Pulmonary Embolism. A First Randomised, Placebo-Controlled, Double-Blind Trial.

Gerard M.J. Bos, MD, PhD, Martin Heijer den, MD, PhD, Huub Willems, MD, Henk Blom, PhD, Wim Gerrits, MD, Marco Cattaneo, MD, Sabine Eichinger, MD, Frits Rosendaal, MD

Blood (2004) 104 (11): 489.

https://doi.org/10.1182/blood.V104.11.489.489

Published: 2004

NARROW

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Effective Alloreactive NK Cell Therapy for Breast Cancer In Mice Requires Conditioning with Cyclophosphamide and Total Body Irradiation but Not Bone Marrow Engraftment

Role of Human NK Cells in Dentric-Cell Based Vaccine.

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Keratinocyte Growth Factor Ameliorates Acute Graft-versus-Host Disease in a Novel Nonmyeloablative Haploidentical Transplantation Model.

Homocysteine Lowering by B Vitamins and the Secondary Prevention of Deep-Vein Thrombosis and Pulmonary Embolism. A First Randomised, Placebo-Controlled, Double-Blind Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only